The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 21.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
SS Innovations International, Inc.
SSII · Nasdaq · USD · Market cap $381M · 483 employees
SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India, Philippines, Indonesia, South America, Iraq, Cyprus, Oman, United Arab Emirates (UAE)…
PASS · Titan Ethical · score 70.0Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price1.66 USD at the 13 Nov 2026 close
- Fair valueUnder review: only one analyst covers it, too few to cross-check it; our model's value is 2.98x the price, above our 2.00x limit.
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenPasses, score 70.0 out of 100
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-13).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
SS Innovations International, Inc. holds its Distribution at $1.66. Consolidating, no directional conviction, held for 523 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 523 days |
| Price at the screen | $1.66 |
| Valuation | N/A trailing · -31.67 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.94 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 19.35% | Below 33% | Interest-bearing debt is just 19.3% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 21.02% | Below 49% | Money owed to the company is 21.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 2.69% | Below 5% | Only 2.7% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
SS Innovations International, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 19%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SSII's ethical verdict changes
Today SSII passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Only one analyst covers it, too few to cross-check it; our model's value is 2.98x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
Price History & ProjectionsWhere our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -31.7x |
| EPS, trailing | -0.06 |
| EPS, forward | -0.06 |
| Revenue growth | +39.4%strong top-line growth |
| Profit margin | -23.7%currently unprofitable |
| Return on equity | -26.1%not currently earning a positive return on equity |
| FCF yield | -1.02% |
| Debt to equity | 0.33minimal debt: a conservative balance sheet |
| Current ratio | 2.24comfortably covers its short-term bills |
| Beta | 0.94steadier than the market |
| Short interest, float | 0.00% |
| 52-week range | 1.69 - 7.77 |
| Market cap | $381M |
| Employees | 483 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to India and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSSII trades on Nasdaq (the company is based in India). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 21.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 16%. Our forward projection puts the odds of a 10% gain over the next month near 27%. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- SS Innovations International (SSII) Promotes Vishwa Srivastava to President, Appoints Gary Lo CFO Yahoo Finance · 3d ago
- SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion Yahoo Finance · 4d ago
- SS Innovations International (SSII) CEO Outlines Growth Strategy as SSi Mantra Expands Robotic Surgery, Telesurgery, and Global Reach Yahoo Finance · 10d ago
- SS Innovations International (SSII) Demonstrates Long-Distance Robotic Cardiac Surgery at Industry Events Yahoo Finance · 14d ago
- SS Innovations International (SSII) Showcases Robotic Telesurgery Capabilities at International Medical Conferences Yahoo Finance · 21d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $4.08 | -13.7% | · | $863 | -13.7% |
| 2 months | $4.30 | -18.1% | · | $819 | -18.1% |
| 3 months | $4.96 | -29.0% | · | $710 | -29.0% |
| 6 months | $5.82 | -39.5% | · | $605 | -39.5% |
| 1 year | $4.20 | -16.2% | · | $838 | -16.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SSII does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.